{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:00:43Z","timestamp":1793721643465,"version":"4.6.1"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,10,1]]},"DOI":"10.1001\/jamaoncol.2021.3441","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T15:36:23Z","timestamp":1629992183000},"page":"1536","source":"Crossref","is-referenced-by-count":46,"title":["Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma"],"prefix":"10.1001","volume":"7","author":[{"given":"Sumanta K.","family":"Pal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Mortazavi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Milowsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Cancer Center, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung","family":"Lyou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kentucky Markey Cancer Center, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kansas Medical Center, Westwood"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Teply","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia Cancer Center, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin Cancer Center, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Michaelson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hoimes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford Cancer Center, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Y.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"coi210051r1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi210051r2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi210051r3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma.","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi210051r4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma.","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"coi210051r5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"coi210051r6","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"10236","key":"coi210051r7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"coi210051r8","doi-asserted-by":"publisher","first-page":"S1155","DOI":"10.1016\/j.annonc.2020.08.2252","article-title":"LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361.","volume":"31","author":"Alva","year":"2020","journal-title":"Ann Oncol"},{"issue":"15","key":"coi210051r9","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2019.37.15_suppl.4503","article-title":"CALGB 90601 (Alliance): randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi210051r10","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy.","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"coi210051r11","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"issue":"14","key":"coi210051r12","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.v5i14","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"coi210051r13","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.3892\/or.2017.5580","article-title":"Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.","volume":"37","author":"Liu","year":"2017","journal-title":"Oncol Rep"},{"issue":"8","key":"coi210051r14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","article-title":"The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression.","volume":"17","author":"Wallez","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"27","key":"coi210051r15","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors.","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi210051r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"16","key":"coi210051r17","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1002\/cncr.28146","article-title":"Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.","volume":"119","author":"Galsky","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"coi210051r18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"25","key":"coi210051r19","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer.","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"coi210051r20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer.","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"coi210051r21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1200\/JCO.19.01395","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies.","volume":"38","author":"Carlo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi210051r22","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1038\/s41467-020-19971-8","article-title":"Common germline-somatic variant interactions in advanced urothelial cancer.","volume":"11","author":"Vosoughi","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"coi210051r23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2020.38.6_suppl.440","article-title":"Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): results from ATLAS, a phase II open-label trial.","volume":"38","author":"Grivas","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi210051r24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat Struct Mol Biol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2783527\/jamaoncology_pal_2021_oi_210051_1634002239.92289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T16:49:10Z","timestamp":1634834950000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2783527"}},"subtitle":["A Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.3441","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}